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Essentials
• Anti-factor (F) VIII antibody formation is a major complication in the treatment of hemophilia A.
• We investigated uptake of FVIII and FVIII immune complex by bone marrow derived dendritic cells.
• Immune complex formation increased uptake of FVIII 3-4 fold in a Fcc receptor dependent manner.
• FVIII immune complex binding to Fcc receptors may modulate immune tolerance induction.
Summary. Background: A major complication in the treatment of hemophilia A is the development of inhibitory antibodies targeting coagulation factor VIII (FVIII). Eradication of these inhibitors can be established by immune tolerance induction (ITI), which consists of daily administration of high dosages of FVIII. FVIII immune complexes (FVIII-IC) could be formed following FVIII infusion in patients with pre-existing anti-FVIII antibodies. Objectives: Here we studied endocytosis of FVIII-IC by bone marrow-derived dendritic cells (BMDCs). Methods: BMDCs were pulsed with FVIII/ FVIII-IC and uptake was assessed by flow cytometry and confocal imaging. Results: BMDCs were able to efficiently internalize FVIII-IC in a dose-dependent manner, 3-4-fold more efficiently when compared with equimolar concentrations of non-complexed FVIII. Uptake of 
Introduction
Hemophilia A is an X-linked bleeding disorder caused by decreased levels of human coagulation factor VIII (FVIII). Disease severity can be categorized according to residual FVIII activity levels, where < 1 IU dL À1 is defined as severe hemophilia A. Without appropriate treatment, patients with severe hemophilia A suffer from spontaneous joint and muscle bleedings. Conventional prophylactic treatment for severe patients consists of regular intravenous FVIII administration [1] . In approximately 25% of patients with severe hemophilia A, inhibitory antibodies against FVIII develop that prohibit treatment with FVIII [2] . These so-called FVIII inhibitors are primarily composed of IgG1 and IgG4 isotypes and have undergone affinity maturation through somatic hypermutation [3] [4] [5] [6] . Both somatic hypermutation and class switching are processes that are dependent on CD4 + T cells. CD4 + T-cell and B-cell responses targeting FVIII have been extensively characterized in hemophilia A patients [7] [8] [9] [10] [11] and hemophilic mice [12] [13] [14] [15] [16] . The initial step in inhibitor formation comprises the endocytosis of FVIII by professional antigen presenting cells (APCs) such as dendritic cells (DCs). DCs can endocytose antigens either in a soluble form or through the uptake of larger particles such as opsonized bacteria, exosomes and apoptotic or necrotic cells. Antigens are subsequently processed into peptides in the endo-lysosomal compartments and the resulting peptides are presented in association with major histocompatibility complex (MHC) on the cell surface [17] . Endogenous antigens are typically loaded on MHC class I molecules and presented to CD8 + T cells, whereas peptides derived from exogenous antigens presented on MHC class II can activate CD4 + T cells. Immune tolerance induction (ITI) treatment, which consists of regular infusions of high concentrations of FVIII, is used to reduce inhibitor titers [18] . Once patients have developed circulating anti-FVIII antibodies, FVIIIIgG immune complexes (FVIII-ICs) can form upon infusion of FVIII. A number of studies have provided evidence for the presence of FVIII containing immune complexes (FVIII-IC) in patients with hemophilia A [19, 20] and acquired hemophilia A [21] . Recently, noninhibitory FVIII binding IgG has been shown to modulate the FVIII half-life in hemophilia A patients without inhibitors [22] . FVIII-IC may be composed of both inhibitory and non-inhibitory anti-FVIII antibodies [22] [23] [24] [25] . In analogy with other antigens, FVIII-IC may not only affect the FVIII half-life, but may also modulate immune responses [26] . It has been shown that DCs (but not macrophages or B cells) activate MHC class II-restricted memory CD4 + T cells in vivo after injection of immune complexes [27] . These findings show that antibodies in complex with antigen can modulate the antibody response to the same antigen [28] . IgG can have a suppressive effect, which is therapeutically exploited in anti-Rhesus D prophylaxis, or an enhanced effect as is generally observed for soluble antigens [28] .
Even though FVIII-containing ICs are presumably readily formed during ITI in hemophilia A patients, the processing of these FVIII-ICs has not yet been described in the literature. Here we studied endocytosis of FVIII-IC using murine bone marrow-derived DCs (BMDCs) as a model system. These cells have been shown to express high-affinity receptor FccRI, which is capable of binding soluble IgG [29] . Also the low-affinity receptors, which bind IgG complexes under physiological conditions, are expressed on BMDCs (see Fig. S1 ) [29] . The low-affinity FccRIIb receptor contains a cytosolic immunoreceptor tyrosine-based inhibition motif (ITIM), whereas the cytoplasmic tail of the associated FcRc-chain of the other family members contains an immunoreceptor tyrosine-based activation motif (ITAM) [29] . In this study we addressed the role of individual members of the Fcc receptor family in the uptake of FVIII-IC by BMDCs.
Methods

Materials
Mouse recombinant GM-CSF (R&D System, Minneapolis, MN, USA) Granulocyte macrophage colonystimulating factor (GM-CSF, R&D systems, Minneapolis, MN, USA) was used for culturing murine bone marrowderived dendritic cells (BMDCs). Penicillin/streptomycin and RPMI-1640 medium were from Lonza (Walkersville, MD, USA). Fetal calf serum was purchased from Bodinco (Alkmaar, the Netherlands). Ninety-six-well microtiter plates were purchased from Nunc (Roskilde, Denmark). Antibodies used were: 2.4G2 (Miltenyi Biotech, Auburn, CA, USA) and mouse anti-FccRI (clone X54-5/7.1, IgG1, BD Biosciences, San Jose, CA, USA), mouse anti-FccRIIb (clone ly17.2 produced in house, IgG2a), APC-labeled rat anti-FccRIII (clone 275003, IgG2a, R&D systems) and fluorescein isothiocyanate (FITC)-labeled rabbit anti-FccRIV (Clone 012, IgG; Sino Biologicals, Beijing, China). Alexa Fluor 488-labeled goat anti-mouse IgG1 and goat anti-mouse IgG2a (Life Technologies, Carlsbad, CA, USA) were used as a secondary antibody for detection of FccRI and FccRIIb, respectively. As a control for FccRI and FccRIIb, cells were stained only with these secondary antibodies. Appropriate isotype controls were used for FccRIII and FccRIV: APC-labeled rat IgG2a as control for FccRIII (eBioscience, San Diego, CA, USA) and FITC-labeled rabbit IgG for FccRIV (GenScript, Piscataway, NJ, USA). Monoclonal anti-FVIII antibodies ESH4 and ESH5 (Sekisui Diagnostics, Stamford, CT, USA) have been used for FVIII immune complex formation as well as monoclonal antibodies CLB-CAgA, CLB-CAg9, CLB-CAg12 and CLB-CAg117, which are produced in-house and have been described previously (see Fig. 1B for IgG isotypes) [30] [31] [32] [33] . For CD11c detection a hamster anti-CD11c (APC labeled, IgG1) was used (BD bioscience). As a control, cells were stained with an isotype control from the same company. MHC class II was detected with Phycoerythrin (PE)-labeled IgG2a mouse anti-MHCII (Affymetrix, eBioscience). A PE-labeled isotype control was used from the same company. Paraformaldehyde 20% EM grade was supplied by Electron Microscopy Sciences (Hatfield, PA, USA).
Fluorescent labeling of recombinant FVIII
Recombinant full-length human FVIII was kindly provided by B.M. Reipert (Baxter Healthcare Corporation, Vienna, Austria). FVIII was labeled using the Alexa Fluor 488 protein-labeling kit (Life Technologies). Protein concentration and efficiency of labeling were spectrophotometrically determined at 280 and 495 nm. The preparations used for this study contained on average 4.7 Alexa Fluor 488 molecules per molecule of FVIII. Aliquots of FVIII-488 were snap frozen and stored at À80°C. The integrity of labeled FVIII (FVIII-488) was confirmed by SDS-PAGE (data not shown).
Mice
Mice were housed and all animal experiments were performed at the SPF animal facilities of the laboratory animal facility (PDC) of the Leiden University Medical Center (LUMC). All mouse studies were approved by the LUMC Institutional Review Board and performed in accordance with national guidelines and regulations. C57BL/6 mice were purchased from Charles River, Den Bosch the Netherlands. All FccR knockout (KO) mouse models were generated in the transgenic mouse facility of the LUMC, either in pure C57BL/6 background (FccRIIb, FccRIII and FccRIV KO and their combinations) or extensively (n > 12) backcrossed into C57BL/6 background (FccRI KO) and genotyped before use. The FccRI KO mice [34] and FccRIIB KO [35] mice have been described before. A description of the generation of the FccRIII KO, FccRIV KO, FccRIII/IV KO and FccRI/II/III/IV quadruple KO mice will be submitted for publication elsewhere (manuscript in preparation, J.S. Verbeek). FccRIII and FccRIV-deficient mice were generated by genetic ablation of a floxed ligand-binding EC2 domain encoding exon 4 (manuscript in preparation, J.S. Verbeek). FccRIII/IV KO mice were generated by genetic ablation of a floxed 29.1 kb genomic region spanning exon 4 and TM/C domain encoding exon 5 of both FccRIII and FccRIV (manuscript in preparation, J.S. Verbeek). Combined FccRIII/IV KO mice were crossed with FccRI KO mice to generate FccRI/III/IV KO mice. FccRI/II/III/IV quadruple KO mice have been used in previous studies and will be described elsewhere (manuscript in preparation, J.S. Verbeek) [36] [37] [38] .
Size exclusion chromatography and Western blot analysis
The € AKTA purification system was used in combination with a Superdex 200 10/30 GL column (GE Healthcare, Little Chalfont, UK) for detection of FVIII-IC. As a running buffer, Tris buffered saline (TBS) supplemented with 5 mM CaCl and 0.2% Tween 20 at pH 7.4 was used. Fractions of 400 lL were collected in siliconized glass tubes and subsequently analyzed by Western blot using 4-12% NuPage Novex gels (Thermo Fisher, Waltham, MA, USA). FVIII light chain was detected with CLBCAg69 HRP-labeled (in-house) mouse IgG with HRPlabeled sheep anti-mouse IgG (Life Technologies) and developed using TMB blotting (Kem-En-Tec Diagnostics, Taastrup, Denmark).
Generation of BMDCs
Murine BMDCs were essentially prepared as described before [39] . In brief, bone marrow cells were isolated by flushing femurs and tibias with phosphate buffered saline (PBS) supplemented with 2% fetal calf serum (FCS). After erythrocyte lysis, cells were resuspended at 1 9 10 6 cells/ml density and cultured for 6 days in RPMI 1640 medium containing 20 ng mL À1 mouse recombinant GM-CSF and supplemented with 2.5 mM HEPES, 55 lM 2-mercaptoethanol, 100 U mL À1 penicillin, 100 lg mL DCs were incubated with various concentrations of FVIII-488 or FVIII-488 pre-complexed with antibodies at 37°C for 1 h in serum-free CellGro cell culture medium (CellGenix, Freiburg, Germany). Uptake was analyzed by flow cytometry on daily calibrated flow cytometers (FACSCANTO II, LSR II or LSRFortessa flow cytometer; BD Biosciences). Histograms were processed using FlowJo Version 10 software (TreeStar, Ashland, OR, USA).
Confocal microscopy
Confocal microscopy was performed as described previously [40] . Per condition, 0.8 9 10 6 cells were pulsed with 10 nM FVIII/FVIII-IC or 50 nM of mouse IgG pool alone and incubated for 1 h. Next cells were washed with TBS and fixed with 4% paraformaldehyde in TBS at room temperature for 15 min. Samples were subsequently incubated in TBS supplemented with 50 mM NH 4 Cl, 0.5% bovine serum albumin (BSA) and 0.2% saponine for 15 min at room temperature. IgG and CD206 were stained in TBS supplemented with 0.5% BSA, 1 : 500 mouse Fc block (2.4G2, Miltenyi Biotech) and 0.05% saponine. The mannose receptor was stained using an Alexa Fluor 647-labeled rat anti-mouse CD206 (Bio-Rad, Veenendaal, the Netherlands). Cells were mounted using MOWIOL (Calbiochem, EMD Millipore, Billerica, MA, USA) supplemented with 2.5% triethylenediamine (Sigma-Aldrich, St Louis, MO, USA) and 1 lg mL À1 Hoechst 33342 Fluorescent Stain (Life Technologies). Cells were imaged using 639 objective on a Leica TCS SP8 confocal microscope and analyzed using Leica Application Suite X (Leica Microsystems, Wetzlar, Germany).
Statistical analysis
Statistical analysis was performed using Graphpad Prism 6 (GraphPad Software, Inc. La Jolla, CA, USA). Significance between groups of measured mean fluorescent intensities was assessed using a Dunnett test for multiple comparisons or a Student's t-test where indicated.
Results
Formation and characterization of FVIII-IC
In this study we evaluated the internalization of FVIIIcontaining immune complexes (FVIII-IC) by murine bone marrow-derived dendritic cells (BMDCs). FVIII was fluorescently labeled with Alexa Fluor 488 before incubation with a pool of six monoclonal IgGs (CLB-CAgA, CLBCAg9, CLB-CAg12, CLB-CAg117, ESH4 and ESH5) targeting distinct epitopes on FVIII (Fig. 1A,B ) in a 5-fold molar excess of total IgG over FVIII. Formation of FVIII-IC was evaluated using gel filtration chromatography (Fig. 1C ) and the content of FVIII and IgGs in the eluted fractions was determined using Western blot analysis (Fig. 1D) . A single distinct peak was observed when IgG was analyzed (Fig. 1C) ; a broader peak was observed when FVIII was analyzed, probably reflecting the intrinsic heterogeneity of FVIII (Fig. 1C) . Analysis of FVIII-IC samples revealed two peaks comprising fractions 5-7 and 15-17. The early eluting peak (5-7) was composed of FVIII and IgGs, confirming the formation of FVIII-IC; Western blot analysis revealed that the second peak (15-17) was composed of IgG only (Fig. 1C) . No free FVIII was detected, indicating that all FVIII was complexed to IgG, whereas the excess, residual free IgG migrated in a separate peak, as expected.
Endocytosis of FVIII-IC is more efficient when compared with FVIII
To study the effect of immune complex formation on the uptake of FVIII, we pulsed BMDCs with increasing concentrations of FVIII or FVIII-IC and measured binding/ uptake by flow cytometry. FVIII-IC was efficiently internalized by BMDCs in a dose-dependent manner ( Fig. 2A and B) Moreover, endocytosis of FVIII-IC at the highest concentration was more than three times more efficient when compared with equimolar concentrations of soluble FVIII ( Fig. 2A,B) . To determine whether FVIII-IC is internalized and not only bound to the cell surface we visualized the BMDCs treated with FVIII/FVIII-IC using confocal microscopy. BMDCs were incubated with 10 nM FVIII or equivalent amounts of FVIII-IC for 1 h at 37°C, after which cells were fixed and stained for mouse IgG (red). In agreement with previous observations in macrophages [41] , FVIII-488 (green) localized to endocytic vesicles as indicated by co-staining with CD206 (Fig. 2C) . Co-staining of FVIII-488 and IgG was observed following internalization of FVIII-IC (Fig. 2C) . This indicates that both FVIII-IgG and IgG are internalized and end up in the same intracellular compartment.
Enhanced uptake of FVIII-IC does not lead to alterations in cytokine production
Previously it has been shown that FVIII does not activate human monocyte-derived dendritic cells [42] . This prompted us to study whether the uptake of FVIII and FVIII-IC results in upregulation of cytokine expression, as for example observed following activation of dendritic cells. We have used a multiplex assay that measured expression of a number of relevant cytokines such as IL-10 and IL-12. No major changes in expression levels of these cytokines were observed following a 24-h incubation of BMDCs with FVIII, FVIII-ICs or anti-FVIII antibodies (Fig. S3) . Lipopolysaccharide (LPS) was used as a control for these experiments; consistent with literature findings, pronounced changes in expression levels of cytokines such as IL-10 and IL-12 were observed upon incubation with LPS. These findings suggest that FVIIIICs by themselves do not contribute to immune stimulation of BMDCs.
Endocytosis of FVIII immune complexes is mediated via Fcc receptors
We subsequently investigated whether uptake of FVIII-IC is dependent on Fcc receptors. Therefore, we incubated BMDCs with 10 lg mL À1 monoclonal antibody 2.4G2, which interferes with the binding of IgG to FccRIIb and FccRIII [43] . It has also been reported that 2.4G2 binds to high-affinity receptor FccRI via its Fc portion [43] . Cells were incubated with 2.4G2 for 15 min at 4°C and subsequently incubated with either FVIII or FVIII-IC for 1 h at 37°C to allow for internalization. As expected, pre-incubation of DCs with 2.4G2 and subsequent spiking with 10 nM FVIII, did not decrease the uptake of FVIII by DCs (Fig. 3A,B) ; a reduced uptake of 10 nM FVIII-IC was, however, observed following pre-incubation with 2.4G2 (Fig. 3A,B) . Next, increasing concentrations of FVIII or FVIII-IC were added to the cells for 1 h at 37°C in the presence or absence of 2.4G2. Flow cytometry analysis revealed that addition of 2.4G2 strongly reduced the uptake of FVIII-IC (Fig. 3D) . The uptake of FVIII was not reduced in the presence of 2.4G2 To confirm that FVIII-IC is internalized as a complex, BMDCs were incubated with 10 nM FVIII-IC (FVIII, green), fixed and stained for IgG (red), CD206 (white) and the nucleus (blue) for confocal analysis. Samples were images using 639 objective on a Leica TCS SP8 confocal microscope. (Fig. 3C) . These results indicate that Fcc receptors mediate the uptake of FVIII-IC by BMDCs.
To investigate the role of individual Fcc receptors in endocytosis of FVIII-IC, BMDCs from Fcc receptor-deficient mice were isolated. Wild-type C57BL/6 mice, expressing all functional Fcc receptors (FccRI, FccRIIb, FccRIII and FccRIV), were used as a source for wildtype cells. BMDCs were pulsed with increasing concentrations of either FVIII or FVIII-IC for 1 h at 37°C, after which endocytosis was measured by flow cytometry. First, we analyzed the uptake of FVIII by BMDCs of mice lacking all four Fcc receptors. In contrast to wild-type BMDCs no enhanced uptake of FVIII-IC was observed in BMDCs of FccRI-IV-deficient mice (Fig. 4A) . These data show that enhanced uptake of FVIII-IC is mediated by Fcc receptors. Next we analyzed uptake of FVIII and FVIII-IC by BMDCs of mice lacking FccRI, FccRIIb, FccRIII or FccRIV. FccRI-deficient BMDCs displayed an enhanced uptake of FVIII-IC (Fig. 4B) , suggesting that the lack of the high-affinity FccRI receptor does not abolish the enhanced uptake of FVIII-IC. Similarly, FVIII-IC were also efficiently internalized by BMDCs derived from mice lacking FccRIIb, FccRIII or FccRIV (Fig. 4C-E) . Overall, these results indicate that multiple In view of the potential immune-modulatory effects of FVIII-IC, we also determined whether BMDCs expressing only FccRIIb were capable of internalization of FVIII-IC. BMDCs expressing exclusively FccRIIb were prepared from mice lacking the activating FccRI, FccRIII and FccRIV receptors. BMDCs expressing only the inhibitory FccRIIb efficiently internalized FVIII-IC (Fig. 4F) . These results show that the inhibitory FccRIIb, when expressed alone, can also promote the internalization of FVIII-IC. When comparing levels of FVIII uptake following incubation of BMDCs from mice of different genetic backgrounds with 10 nM FVIII, BMDCs lacking FccRI, FccRIIb, FccRIII, FccRIV and FccRI,III,IV combined, all showed statistically enhanced uptake of FVIII-IC when compared with FVIII uptake by wild-type BMDCs (Fig. 4G) . Taken together, these data show that formation of FVIII-IC can lead to an increased uptake by BMDCs in an Fcc receptor-dependent manner. Moreover, internalization of FVIII-IC is mediated by both inhibitory and activating Fcc receptors.
Discussion
FVIII inhibitor development is a major complication of hemophilia care [44] . The development of FVIII inhibitors precludes further treatment with FVIII; bleeding episodes in these patients are managed by FVIII bypassing therapies [45] . Pioneering work by Brackmann and coworkers has resulted in the development of a therapeutic treatment called immune tolerance induction (ITI) that consists of frequent administration of high dosages of FVIII [18, 46] . Although the underlying mechanism of ITI is not fully understood, eradication of FVIII inhibitors is successful in 70-85% of patients [47] . Administration of FVIII in patients with pre-existing inhibitors will result in the formation of FVIII-containing immune complexes (FVIII-IC). Up to now, our knowledge on the biological role of FVIII-IC in inhibitor development is limited. In this study we investigated the effect of immune complexes on the uptake of FVIII by BMDCs. We showed that FVIII-IC is 3-4-fold more efficiently internalized by BMDCs compared with equimolar levels of FVIII. Our findings also show that uptake of FVIII-IC is Fcc receptor mediated and that multiple receptors are involved in the uptake of FVIII-IC. We furthermore explored how BMDCs respond to FVIII-IC using cytokine production as a readout. In contrast to LPS-treated cells, no major changes in the cytokine production profile were observed after FVIII-IC stimulation, suggesting a limited role of FVIII-IC in DC activation. We did not investigate whether the exposure of DCs to FVIII-IC modifies the response in the presence of additional stimuli that target pattern recognition receptors on DCs. This will be an interesting area for future studies.
Each member of the murine Fcc receptor family has a distinct affinity for each IgG subclass [29] . Whereas FccRI binds with the highest affinity to IgG2a and IgG2b antibodies, the inhibitory FccRIIb and the activating FccRIII preferentially bind to immune complexes composed of IgG1. In our experiments we used a panel of monoclonal antibodies of different subclasses for the formation of FVIII-IC; this may explain why we did not observe abrogated uptake of FVIII-IC when BMDCs of mice lacking individual members of the FccR family were used. This does, however, better reflect the in vivo situation where a broad range of IgG isotypes are present in the circulation.
The inhibitory FccRIIb is the only Fcc receptor that is expressed by B cells [48] . Binding of immune complexes to FccRIIb receptor has been shown to modulate secondary immune responses. Indeed, cross-linking of this receptor with the B-cell receptor has been shown to prevent B-cell proliferation in an antigen-specific manner [48] . In addition, it has recently been shown that FccRIIb is critically involved in the differentiation of B cells into antibody-secreting cells [49] . Our data show that BMDCexpressed FccRIIb by itself is capable of mediating FVIII-IC internalization. This finding raises the possibility that FVIII-IC may modulate B-cell responses in hemophilia A through binding to inhibitory FccRIIb.
FccRI is the sole high-affinity IgG receptor and thus able to bind monomeric IgG. It has been postulated that FccRI is continuously saturated with monomeric IgG, thereby preventing binding of immune complexes; however, this has been disputed in the human system [50] . Furthermore, FccRI null mice show impaired antibodydependent cellular processes such as phagocytosis and antigen presentation [51, 52] . Here, we found a modest reduction in FVIII-IC internalization in BMDCs derived from FccRI-deficient mice when compared with wild-type BMDCs. The uptake of FVIII-IC by FccRI-deficient mice was not statistically different from that of BMDCs derived from wild-type mice (data not shown). Polymorphisms in human FccR have recently been explored as a potential risk factor for inhibitor development in patients with hemophilia A [53] . The FCGR2A polymorphism 131R > H increases the risk of inhibitor formation more than 3-fold in hemophilia A patients [53] . Substitution of arginine for a histidine at amino acid position 131 in the activating FCGR2A, leads to an increased affinity for both IgG1 and IgG2, while the affinity of IgG3 and IgG4 is unaffected [29] . Inhibitors of IgG1, IgG2 and IgG4 subclasses are commonly detected in hemophilia A patients. In hemophilia A patients without detectable FVIII inhibitors, low-affinity anti-FVIII antibodies of subclass IgG1 have been detected [54] . One could speculate that enhanced binding of IgG1 containing immune-complexes to FccRIIa131H promotes uptake of FVIII, thereby lowering the threshold for development of high-affinity, inhibitory anti-FVIII antibodies. The reported association between the human FCGR2A R131H polymorphism and inhibitor development was not identified in the genome wide association study (GWAS) of Astermark and co-workers and a recent whole-exome sequencing analysis by Gorski and co-workers. [55, 56] Further study is needed to define the putative role of the FCGR2A R131H polymorphism in inhibitor development.
As the FccR family in mice is distinct from the human family, caution is needed to extrapolate data from this manuscript to uptake of FVIII-IC by human APCs. In mice, four FccR family members have been identified, whereas in humans six different Fcc receptors have been described [26] . Despite similarities in both genomic location and sequence between human and mouse Fcc receptors, there are many differences between the FccR families. Allelic variants further diversify the functional properties of the human FccR family [29] . Despite these differences, mouse models have given valuable information on the role of various Fcc receptors in immunity, various disease models and antibody therapy, as many basic principles are applicable to both the human and murine system. 
